- Biogen (NasdaqGS:BIIB) has agreed to acquire Apellis Pharmaceuticals, adding two commercial immunology and rare disease products to its portfolio.
- The company has received FDA approval for a High Dose Regimen of SPINRAZA for spinal muscular atrophy, based on pivotal trial data in infants.
- Both moves expand Biogen's presence in neurology and rare diseases, with implications for its pipeline mix and revenue sources.
Biogen is known for its focus on neurology and rare diseases, and the Apellis acquisition fits squarely into that profile. For readers tracking large cap biotech, these developments come as the sector continues to see large acquisitions centered on rare conditions and specialty medicines, where product differentiation can be meaningful.
For investors following NasdaqGS:BIIB, the combination of a new late stage platform from Apellis and a higher dose SPINRAZA regimen creates fresh catalysts to monitor. The key questions now are how Biogen integrates Apellis' assets, how quickly the High Dose SPINRAZA regimen is adopted in clinical practice, and what that might mean for the mix of revenue across Biogen's key franchises.
Stay updated on the most important news stories for Biogen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Biogen.
3 things going right for Biogen that this headline doesn't cover.
Quick Assessment
- ✅ Price vs Analyst Target: At US$172.34, Biogen trades about 17% below the US$207.33 analyst price target.
- ✅ Simply Wall St Valuation: Shares are described as trading 52.8% below an estimated fair value, which is a wide discount.
- ❌ Recent Momentum: The 30 day return of about 6.8% decline shows weak short term sentiment.
There is only one way to know the right time to buy, sell or hold Biogen. Head to Simply Wall St's company report for the latest analysis of Biogen's Fair Value.
Key Considerations
- 📊 The Apellis deal and High Dose SPINRAZA approval both increase Biogen's exposure to commercial rare disease assets, which can reshape future revenue mix.
- 📊 Watch how quickly clinicians adopt the higher SPINRAZA dose in SMA and how Apellis products contribute to earnings versus the current P/E of 19.6 and forward P/E of 14.1.
- ⚠️ One flagged risk is that large one off items have affected reported results in the past, so keep an eye on how integration costs and transaction items show up in upcoming reports.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Biogen analysis. Alternatively, you can visit the community page for Biogen to see how other investors believe this latest news will impact the company's narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com